Serrated Polyposis: An Enigmatic Model of Colorectal Cancer Predisposition by Rosty, Christophe et al.
SAGE-HindawiAccess to Research
Pathology Research International
Volume 2011, Article ID 157073, 13 pages
doi:10.4061/2011/157073
Review Article
Serrated Polyposis: AnEnigmaticModel ofColorectal Cancer
Predisposition
ChristopheRosty,1,2 Susan Parry,3,4 and Joanne P.Young2,5
1Pathology Queensland and UQ Centre for Clinical Research, Royal Brisbane and Women’s Hospital, Herston, QLD 4029, Australia
2Familial Cancer Laboratory, QIMR, 300 Herston Road, Herston, QLD 4006, Australia
3New Zealand Familial Gastrointestinal Cancer Registry, Auckland City Hospital, Auckland 1142, New Zealand
4Department of Gastroenterology and Hepatology, Middlemore Hospital, Auckland 1640, New Zealand
5The University of Queensland School of Medicine, Herston, QLD 4006, Australia
Correspondence should be addressed to Joanne P. Young, joanne.young@qimr.edu.au
Received 11 November 2010; Revised 12 February 2011; Accepted 25 February 2011
Academic Editor: Wade Samowitz
Copyright © 2011 Christophe Rosty et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Serrated polyposishasonlyrecently been accepted asaconditionwhich carries anincreased personalandfamilialrisk ofcolorectal
cancer. Described over four decades ago, it remains one of the most underrecognized and poorly understood of all the intestinal
polyposes.Withavarietyofphenotypicpresentations,itislikelythatserratedpolyposisrepresents agroupofdiseasesratherthana
single entity. Further, neoplastic progression in serrated polyposis may be associated with premature aging in the normal mucosa,
typiﬁed by widespread gene promoter hypermethylation. From this epigenetically altered ﬁeld, arise diverse polyps and cancers
which show a range of molecular features. Despite a high serrated polyp count, only one-third of colorectal cancers demonstrate a
BRAF V600Emutation,themolecularhallmarkofthecanonicalserrated pathway,suggestingthatthough multipleserratedpolyps
act as a marker of an abnormal mucosa, the majority of CRC in these patients arise within lesions other than BRAF-mutated
serrated polyps.
1.Introduction
Serrated polyposis [1], a condition also known as hyper-
plastic polyposis, was described in the early seventies [2]
and remains to the present day the most under-recognized
and least understood of the colorectal polyposes. Its deﬁning
characteristic, speciﬁcally the presence of numerous col-
orectal epithelial polyps with serrated architecture (Figure 1,
Text Box 1), placed it, until relatively recently, among
conditions without signiﬁcant clinical consequence, based
uponthe perception that all serrated polypswere innocuous.
For decades, the malignant transformation of conventional
adenomas was considered to be the single mechanism
underlying the genesis of colorectal cancer (CRC) [3]. In
the late nineties, a number of important observations set
in motion a major paradigm shift in the way the initiation
and progression of CRC were viewed. These observations
carefully detailed at a molecular level that some serrated
polyps may act as the precursor lesions in an alternative
developmental pathway for CRC, existing alongside the
traditional adenoma-carcinoma sequence [4]. As with the
histological observations suggesting that a subset of serrated
polyps may develop features associated with malignancy [5–
7], clear molecular evidence for the malignant transforma-
tion of serrated polyps was also ﬁrst observed in a patient
with serrated polyposis [8], suggesting that this condition
could serve as a model for the malignant conversion of
serrated polyps, a mechanism which has become known
as the serrated pathway. Today the clinical signiﬁcance of
serrated polyposis rests upon consistent observations in
relatively large studies of an increased personal and familial
risk of CRC [9–12]. To include serrated polyposis as a CRC
predisposition is a concept whose time has come [13].
2.Deﬁnitionand Features
Clinical criteria for the recognition of serrated polyposis
were ﬁrst established in 2000 [14] and were proposed for2 Pathology Research International
1234
mm
cm
Figure 1: Colectomy specimen from a patient with serrated
polyposisshowingmultipleﬂatpolyps onmucosalfolds,measuring
less than 10mm, distributed throughout the colon (courtesy of Dr.
Andrew Clouston, Envoi Pathologists,Brisbane).
two major reasons. Firstly, to delineate it from the clearly
penetrant and clinically severe condition familial adenoma-
tous polyposis (FAP). Secondly, necessarily stringent criteria
ensured that diminutive serrated polyps observed relatively
often in the distal colorectum of older patients, including
those which cluster around rectal cancers, were not included
in the deﬁnition [15, 16]. In serrated polyposis, the serrated
polypsdemonstrate featuresthat distinguish themfrom spo-
radic serrated polyps in that they are unusually numerous.
Theyalsomaybelargeandproximalandmayexhibitatypical
histologicalarchitecture.Whilelargepolypsarepreferentially
located in the proximal colon, small sessile polyps are often
distributed throughout the colorectum [14, 17]. An example
of the gross appearance of a serrated polyposis colon is
shown in Figure 1.
The current revised criteria, published in 2010 [1], are
(1) at least ﬁve serrated polyps proximal to the sigmoid
colon with two or more of these being >10mm,
(2) any number of serrated polyps proximal to the
sigmoid colon in an individual who has a ﬁrst-degree
relative with serrated polyposis,
(3) >20 serrated polyps of any size, but distributed
throughout the colon. The implied meaning of this
last criterion is that the polyps are not all present in
the rectum (Text Box 2).
The individual criteria to deﬁne serrated polyposis have
been diﬃcult to delineate due to the phenotypic plasticity
of this condition, which overlaps with the occurrence of
common sporadic serrated polyps found in the population.
Serrated polyposis may represent a group of diseases or
a continuum which is inﬂuenced by a variety of genetic
and environmental modiﬁers, rather than a single disease.
Therefore, at the time of writing, the current criteria remain
empirical in nature [1].
When establishing the serrated polyp count for an indi-
vidual, Higuchi and Jass have suggested that the polyp count
be cumulative over time [18]. Serrated polyposis aﬀects
both sexes and is most likely to be identiﬁed in persons
aged between 55 and 65 years. It may become apparent
considerably earlier [7, 19–21], particularly if symptoms
such as bleeding, bowel habit alterations, and abdominal
pain result from the polyp burden or advanced neoplasia.
The range ofages at presentation in the literature varies from
11 to 83 years [7, 19–21].
Estimates of the prevalence of serrated polyposis suggest
that it is relatively rare. A large population-based screening
trial of over 40,000 asymptomatic patients aged 55–64
years prospectively identiﬁed serrated polyposis at a rate
of 1 in 3000, with 50% of these demonstrating at least
one synchronous conventional adenoma [22]. Rubio et al.
reported that only 10 cases were observed in a 1026-bed
Scandinavian hospital over a 16-year period [23], whilst
Leggett et al. identiﬁed 12 cases from a similar institution
during a 5-year period [24]. A family history of CRC is
a relatively frequent ﬁnding with ﬁgures of up to 59%
reported [25–27],thoughotherpublicationssuggestthatthis
is rare [28, 29]. A recent large multicentre study from The
Netherlands has estimated the risk to ﬁrst-degree relatives
of CRC to be approximately ﬁvefold that of the general
populationadjusted for demographic variables: RR5.4 (95%
CI 3.7 to 7.8) [10]. Studies of ethnicity suggest that, in
contrast to conditions such as FAP and Lynch syndrome
which can occur in many ethnic groups, serrated polyposis
is a condition largely of north-western Europeans. Obser-
vations from a multiethnic New Zealand gastroenterology
service demonstrated that, in a 24-case series of serrated
polyposis patients, all cases were derived from the European
component, despite only 46% of the attending patients
having European ancestry [17]. Buchanan et al. reported
a prevalence of 95% northern Europeans in a case series
of 126 serrated polyposis patients [11]. Similarly, Kalady
et al. reported that, in a large series of serrated polyposis
patients (n = 115) collected in Ohio, 97% were white [27].
The fundamental defect in serrated polyposis has yet to be
elucidated and may involve defects in inﬂammation and/or
apoptosis. The involvement of widespread DNA methylation
in the normal mucosa of patients with this condition [30]
suggests deregulation of an epigenetic control mechanism,
either directly or as a consequence of upstream genetic
events.
3.Historyof ItsRecognitionasa Colorectal
CancerPredisposition
Described in some earlier reports primarily in order to
distinguish it from FAP, serrated polyposis was originally
considered to have no important clinical consequences [29].
However, today it is recognized as a condition with substan-
tialriskofCRC.Theearlyliteraturecontainsmuchtointerest
thosewho studyserratedpolyposis, andtheserratedpathway
to carcinoma in general. Serrated polyposis was described
as early as 1970 by Goldman et al. [2]. In this case report,Pathology Research International 3
Epithelial polyps with serrated architecture arising in the large intestine were until very recently collectively known as
hyperplastic polyps. A modern classiﬁcationhas now been proposed which uses the descriptive umbrella term serrated
polyps for all epithelial polyps with serrated architecture and the term hyperplastic polyps for the subset of small
common lesions without evidence of abnormal proliferation. A detailed description of the WHO classiﬁcation
of serrated polyps is given in Section 3 of this paper.
Text Box 1: Serrated polyps or hyperplastic polyps? [1].
(1) At least ﬁve serrated polyps proximal to the sigmoid colon with two or more of these being >10mm.
(2) Any number of serrated polyps proximal to the sigmoid colon in an individual who has a ﬁrst-degree relative
with serrated polyposis.
(3) >20 serrated polyps of any size, but distributed throughout the colon.
Text Box 2: Clinical criteria for the identiﬁcation of serrated polyposis [1].
a 42-year-old man presented with 30 serrated polypsranging
in size between 0.75 and 1.5cm. Of particular interest was
the observation of adenomatous transformation within the
polyps, a concept now readily accepted, but somewhat con-
troversial in those earlier times. Despite several reports
relating serrated polyps to the development of adenomatous
change, villous components, and even adenocarcinoma [31–
33], the bulk of investigations published around this time
returned a classiﬁcation of nonneoplastic for serrated polyps
[3, 34–36].
In 1978, Cooke described serrated polyposis as a variant
of FAP [5]. A further report describing cancer and dysplasia
in a background of serrated polyposis was presented in 1979
[37]. In this publication, the authors, whilst suggesting that
hyperplastic polyps were “benign, nonneoplastic prolifera-
tions which unlike tubular and villous adenomas did not
predispose the patient to coloniccancer,” went on to demon-
strate a case of serrated polyposis where hyperplastic adeno-
matous transformation and cancer “had probably occurred,”
and recognized that cancer could be associated with unusual
casesofmultiplehyperplastic polyps[6].In1980,sevencases
of serrated polyposis were recorded from a London hospital
[29], and this became an inﬂuential landmark paper in the
confusion surrounding serrated polyposis. Six of the seven
cases were male, and there was an averageage at presentation
of 37 years. The presence of larger metaplastic polyps was
noted, and the possibility that “metaplastic polyposis” was a
pathological entity was raised [29]. With followup, however,
no cases of CRC were observed, thereby designating serrated
polyposis as a low-risk condition of young males. This
paper inﬂuenced thinking on serrated polyposis for over a
decade.However,duringthe1990sassociationwith CRCwas
revisited by Torlakovic and Snover [7], Burt and Samowitz
[38], and Jeevaratnam and colleagues in a familial setting
[39] and in a small series of patients who were instrumental
in demonstrating the malignant transformation of serrated
polyps [8]. Many series and case reports have now been
published [5–8, 19–21, 23, 24, 26, 28, 39–60]. In the three
largestseriespublishedtodate,25–38%ofpatientspresented
with at least one CRC [9, 12, 27], and multiple CRCs were
common [11]. However, the problem remains that published
series are predominantly composed of retrospective clinic-
based records, and therefore the estimation of CRC risk is
likely to be inﬂated and to reﬂect a CRC risk associated
with symptomatic patients. In addition, the wide variety of
phenotypic presentations within serrated polyposis has the
potential to be associated with varying risk magnitudes. At
the time of writing, no prospectively collected population-
based risk estimates for CRC are available. A summary of
the ﬁndings in published series of serrated polyposis cases
is presented in Table 1.
4.SerratedPolypSubtypes
Serrated polyps are the second most common type of col-
orectal polyps, after conventional adenomas, found during
population colonoscopy. Serrated polyps are also the most
prominent phenotypic feature in serrated polyposis usually
ranging in number from 5 to greater than 150, and varying
greatly in size. In addition, a diverse range of dysplastic
lesions of both conventional and serrated lineages may also
be present.
In a study reporting the prevalence of each polyp type
diagnosed from 179,111 consecutive population colono-
scopies in the United States, Lash and colleagues found that
epithelial benign polyps were classiﬁed as conventional ade-
nomas in 58.6% and as serrated polyps in 41.4% [62]. The
terminology and histologic classiﬁcation of serrated polyps
have been a matter of debate for some years. The most
clinically relevant feature is the presence of dysplasia that
increases the risk of developing CRC and impacts colon-
oscopy surveillance intervals. Therefore, the classiﬁcation
of serrated polyps into dysplastic polyps and nondysplastic
polypsisthemostmeaningful division.However,thereisstill
some degree of confusion in diagnosing serrated polyps with
reported signiﬁcant variation in the detection rate and in
the histologic classiﬁcation, justifying the need for increased
awareness and education [63]. All of the following subtypes
are observed in serrated polyposis.4 Pathology Research International
Table 1: Summary ﬁndings in serrated polyposis from publications reporting more than ﬁve cases (adapted from Buchanan et al., 2010)
[11].
Author Year Cases (n) Mean age at
diagnosis (years)
Number of polyps
observed %w i t hC R C Family history of
CRC
Kalady et al. [27] 2011 115 62 2-multiple 25% 38%
Buchanan et al. [11] 2010 126 49 5–150 40% 59%∗
Boparai et al. [9] 2009 77 56 2–53 35% NS
Carvajal-Carmona
et al. [25] 2007 32 46 11-multiple 25% 59%
Chow et al. [26] 2006 38 44 20-multiple 26% 50%
Renaut et al. [61] 2001 28 58 20-multiple 29% 39%
Yeoman et al. [17] 2007 24 61 5-multiple 54% 17%
Ferr´ andez et al. [28] 2004 15 53 15-multiple 0% 0%
Lage et al. [48] 2004 14 58 19–100 43% 33%
Hyman et al. [43] 2004 13 62 20-multiple 54% 38%
Rashid et al. [54] 2000 13 58 multiple 77% 38%
Leggett et al. [24] 2001 12 57 30–>100 58% 17%
Rubio et al. [23] 2006 10 61 6–159 70% 10%
Spjut and Estrada
[56] 1977 9 53 Multiple 11% NS
Williams et al. [29] 1980 7 37 50–150 0% 14%
Torlakovic and
Snover [7] 1996 6 57 50–100 67% NS
Place and Simmang
[53] 1999 6 60 50–100 50% 14%
NS: not speciﬁed or unknown.
∗Genetics clinic series.
4.1. Nondysplastic Serrated Polyps. Nondysplastic serrated
polyps comprise hyperplastic polyps and sessile serrated
adenomas/polyps, representing the vast majority of all ser-
rated polyps. The use of new high-deﬁnition endoscopes in
association with chromoendoscopy ornarrow-band imaging
has led to a higher detection of these polyps.
4.1.1. Hyperplastic Polyps (HPs). More than 75% of serrated
polyps are HPs [62, 64, 65]. Most often measuring 5mm
or less, HPs are sessile pale lesions, usually found on the
tip of mucosal folds in the distal colorectum, with normal
architecture and normal proliferation characteristics. In the
proximal colon, HPs are often larger and more diﬃcult to
visualize.TheprevalenceofHPsinasymptomaticadultsaged
40 years or more has been estimated to be around 10%
in Western populations [66–68]. In autopsy studies, the
prevalence rate of HPs ranged from 5% in a Cretan study
to 40% in a British study [69–71]. While HPs develop at an
earlier age than conventional adenomas, its incidence does
not seem to signiﬁcantly increase after 50 years, contrasting
with the positive correlation between increased age and the
prevalence of conventional adenoma [72].
Histologically, HP is the prototypical example of
serrated polyps of the colon with a saw-toothed appearance
caused by in-foldings of the crypt lining epithelium in the
upper half of the crypts. All types of HP are characterized
by elongated crypts, with maturation of cells towards the
surface, and proliferation activity limited to the lower
portion of the crypts. HPs are further divided into 3
histologic subtypes: microvesicular, goblet-cell, and mucin-
poor, without clinical relevance as yet. Microvesicular HP
is the most common type, characterized by the presence of
columnar cells with abundant apical vesicular mucin and by
a decreased number of goblet cells. In contrast, goblet-cell
HPs show elongated crypts with numerous goblet cells and
minimal serration limited to the most upper portion of
the crypts. These polyps may be overlooked and are often
underdiagnosed and therefore may occur more frequently
than reports suggest. Finally, mucin-poor HPs are very rare
and display prominent serration, regenerative changes, and
mucin-depleted columnar cells. It is still debated whether
mucin-poor HPs are a true separated subtype or an irritated
form of microvesicular HPs.
4.1.2. Sessile Serrated Adenomas/Polyps (SSA/P). First desig-
nated “serrated polyps with abnormal proliferation” by Tor-
lakovic et al. in 2003, SSA/Ps comprise 15–20% of all
serrated polyps [65]. SSA/Ps are ﬂat or slightly elevated
lesions most commonly found in the proximal colon and
usually measuring more than 5mm. Histologically, SSA/Ps
diﬀer from HPs by the presence of abnormal architectural
features secondary to abnormal proliferation. Whereas the
proliferative zone in HPs is located in the base of the crypts,
it is usually on the sides of the crypts in SSA/Ps, leadingPathology Research International 5
to asymmetrical growth in crypts with an inverted T shape
or L shape. Other histologic features of SSA/Ps include the
presence of mature goblet cells at the bases of the crypts,
hyperserration at the base or throughout the crypts, and
pseudoinvasion of the muscularis propria. Dysplasia is not
present.
4.2. Dysplastic Serrated Polyps
4.2.1. Traditional Serrated Adenomas (TSAs). TSA is a rela-
tively uncommon polyp, comprising up to 5% of serrated
polypsin Western countries with a higherprevalence in Asia,
particularly in Korea [73]. Compared to SSA/Ps, TSAs
are protuberant polyps more frequently found in the left
colon and in older individuals. The architecture of TSA is
often more complex than villous or tubulovillous adenoma,
with prominent serration and ﬁnger-like projections. The
presence of ectopic crypt foci in TSAs, deﬁned by the crypts
with their base not seated at the level of the muscularis
propria, is useful to distinguish them from SSA/P [74].
The neoplastic cells are characterized by an abundant eos-
inophilic cytoplasm and elongated pencillate nuclei. Dys-
plasia in TSA is usually mild, with a diﬀerent appearance
of the dysplasia associated with conventional adenoma
and low proliferative characteristics. However, conventional
adenoma-type dysplasia can also be present and sometimes
with high-grade features.
4.2.2. Sessile Serrated Adenomas/Polyps with Dysplasia
(SSA/P-D). The presence of dysplastic crypts in a SSA/Pwas
often reported aspart ofthe“mixed polyp”group and isnow
better recognized as a speciﬁc category of dysplastic serrated
polyps with malignant potential. In most cases, dysplasia in
SSA/P is similar to dysplasia in conventional adenoma and is
well demarcated from the nondysplastic areas. Dysplasia in
SSA/Ps is rare, found in 14% of all SSA/P in a recent study
by Lash et al. [62]. In this study of over 2000 patients, the
median age for presenting with a nondysplastic SSA/P was
61, increasing to 66 for SSA/P with low-grade dysplasia, 72
for SSA/P with high-grade dysplasia, and 76 for SSA/P with
invasive carcinoma (a span of 15 years). In contrast, the span
between tubular adenoma and non-SSA/P carcinoma is only
5y e a r s .E x a m p l e so fs e r r a t e dp o l y ps u b t y p e sa r eg i v e ni n
Figure 2.
5.Phenotypicand MolecularHeterogeneity
Table 2 shows therates ofmolecularalterations forthemajor
serrated polyp subtype categories, after adding all available
results from various large studies [73, 75–84]. Somatic
molecular alterations associated with serrated polyps have
been well described in previous publications [54, 76, 79, 85–
87] and include BRAF (V600E) mutation, KRAS (codons 12
and13)mutations,MLH1methylation,MGMT methylation,
and CpG island methylator phenotype (CIMP). The preva-
lence of these alterations varies according to the subtype
of serrated polyp. BRAF mutation is the most common
alteration in all polyp types, with the highest rate in SSA/Ps
(83.9%) and the lowest rate in goblet-cell HPs (20%). In
contrast, KRAS mutation is most commonly detected in
goblet-cell HPs (48.4%) and TSA (22.4%). MLH1 methy-
lation ranges from 14.3% in goblet-cell HPs to 47.5% in
TSA.Interestingly,while MLH1methylationdoesoccurquite
frequently, a high-level microsatellite instability phenotype
is very rarely encountered in serrated polyps [76, 88]. MSI-
H is a late and probably an important pivotal event in the
serrated pathway, occurring at the transition between high-
grade dysplasia and invasive carcinoma [76, 89]. MGMT
methylation ranges from 0% in goblet-cell HPs to 74.2%
in TSA. A high level of CIMP, deﬁned by ≥2/5 methylated
markers, occurs in 39% of HPs, 76% of SSA/Ps, and 79% of
TSA [76].
The question of phenotypic heterogeneity in serrated
polyposis can be further considered with an examination
of the reported molecular changes of serrated polyps as
they apply to the syndromic patient. Though there appear
to be at least two phenotypic subtypes which correspond
to the ﬁrst and last criteria (Text Box 2), a previous report
from the UK clearly demonstrates that the predominant
molecular change in the polyps is that of BRAF mutation,
even in patients with numerous polyps [25], and therefore
suggesting that oncogene mutations are of little value in
subtyping this disorder. However, rare cases of serrated
polyposis are reported where KRAS mutations predominate
[25], and current evidence suggests that, in at least some of
these patients, biallelic germline mutation of MUTYH may
be responsible [25, 26, 90, 91].
Although the possibility of these two types of serrated
polyposis was ﬁrst raised over 10 years ago [92], the appli-
cation of such a classiﬁcation to CRC risk may not be readily
implemented. Even though large and dysplastic polyps are
likely to be an indicator of high malignant potential, the
presence of CRC in cases with multiple small HPs [61],
as well as the absence of CRC in many cases of serrated
polyposis [11, 12] with large and dysplastic polyps, argues
against a nonoverlapping classiﬁcation.
6.EpigeneticFieldDefect in
Establishment ofNeoplasia
CRC in general develops through one of two independent
molecular pathways that involve sequences of genomic and
epigenomic alterations associated with pathological and
clinical features: the adenoma pathway in 70–80% and the
serrated pathway in the remaining 20–30%. The somatic
molecular features which characterize the serrated pathway
to CRC include activating mutations in BRAF [81, 83,
86] and widespread hypermethylation of gene promoters
(CIMP) [87] with or without MSI [8, 42]. In the serrated
pathway,theearliestknowneventissomaticBRAF mutation,
found in aberrant crypt foci [93], and with a high rate in
microvesicular HP and SSA/P [76, 85]. The hypermature
cells of the upper crypt in serrated polyps are thought to
result from a mechanism of oncogene-induced senescence
brought about by the presence of an activating BRAF muta-
tion [94]. Escape from senescence is achieved subsequently6 Pathology Research International
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Figure 2: Showing 4 serrated polyp subtypes. (a) Microvesicular hyperplastic polyp with crypt serration and proliferative crypt bases. (b)
Sessileserrated adenoma/polyp,showingasymmetrical serrated crypts anddilated crypts. (c)Traditional serrated adenoma,with prominent
complex serration and hypereosinophilic cells. (d) Sessile serrated adenoma/polypwith high-grade dysplasia (right).
Table 2: Prevalence of genetic and epigenetic alteration in the diﬀerent subtypes of serrated polyps by combining all comparable data from
[73, 75–84].
Polyp type BRAF mutation KRAS mutation CIMP-H∗ MLH1 methylation MGMT methylation
HP
Microvesicular 66.3% 12.3% 47.4% 39.5% 26.3%
Goblet-cell 20% 48.4% 14.3% 14.3% 0%
All subtypes 51.5% 22.1% 38.5% 27% 14.8%
SSA/P 83.9% 5.8% 75.9% 42.6% 25%
TSA 62.5% 22.4% 79.3% 47.5% 74.2%
∗CIMP-H: high level of CIMP in polyps deﬁned by ≥2/5 methylated markers from O’Brien et al. [76, 85].
by the inactivation by promoter methylation of tumour sup-
pressorscontrollingsenescence[95],thusallowing alesionto
progresstoamoreproliferativeneoplasm.Anepigeneticﬁeld
defect present in serrated polyposis would facilitate this pro-
cess more readily [30] with the consequent increase in polyp
numbers which deﬁne the condition. When multiple lesions
are examined, serrated pathway features of BRAF mutation
and CIMP demonstrate a high rate of concordance between
discrete lesions in individuals with serrated polyposis [86,
87]. As would be expected, most CRCs (70%) in serrated
polyposis derive from the proximal colon [17]. An exception
to this occurs in young-onset patients (<50 yrs old) where
the CRCs are more likely to be distal [11, 12, 26]. This is an
under-recognized feature of young-onset serrated polyposis
though it has been mentioned in previous publications [96].
Hypermethylation of gene promoters is also observed in
the normal mucosa of individuals with increasing age [97,
98] and is also more likely to be associated with synchronous
proximal CRC with concordant molecular features [99,
100]. However, in serrated polyposis, increased methylation
of gene promoters is evident even in the normal mucosa
of younger individuals [87, 91, 101], indicating that an
epigenetic regulatory defect may be present in the normal
tissues of these patients and suggesting a prematurely aged
mucosa associated with increased risk for the establishment
ofneoplasia. Ofinterest, in 1968,Arthurobservedthatmeta-
plastic polyps were a marker of age in the normal mucosaPathology Research International 7
[35]. The concept of an epigenetic ﬁeld defect in serrated
polyposis was clearly demonstrated by Minoo et al. in 2006
[30]. Signiﬁcantly the level of methylation in apparently
n o r m a lm u c o s aw a sh i g h e ri ns e r r a t e dp o l y p o s i sp a t i e n t s
when compared to patients with sporadic serrated polyps.
7.Roleofthe ConventionalAdenomain
CancerRisk
The complex biology of serrated neoplasia and the plasticity
of its developmental pathway can give rise to CRC with vari-
able MSI status [8], and to small numbers of apparently con-
ventional adenomas, in addition to multiple serrated polyps.
It has been estimated that conventional adenomas are seen
in up to 90% of serrated polyposis patients [23, 24], raising
the notion that lesser numbers of conventional adenomas
are part of the syndrome. Importantly, the risk for patients
with serrated polyposis to present with a synchronous CRC
at time of diagnosis is signiﬁcantly higher when at least one
conventional adenoma is present [11, 12, 24].
Adenomatous lesions in a serrated polyposis patient may
either evolve from serrated polyps, progressing to a conven-
tional type of dysplasia, or arise via an alternate mechanism.
The presence of “mixed polyps,” as they were previously
known (now called SSA/P with dysplasia), which demon-
strate a very high rate of somatic BRAF mutation (80–90%)
[76] and therefore, byimplication, origin in a serrated polyp,
provides a plausible precursor lesion for the CRC which
arises in serrated polyposis [6, 19, 50, 56, 57]. In contrast,
conventional adenomas almost never harbor a BRAF muta-
tion [84]. If most of the CRCs in serrated polyposis were to
arise from advanced serrated polyps, a high rate of BRAF-
mutatedCRC would be expected. CRCsin serrated polyposis
have shown somatic BRAF mutation in 33% of 6 cases in
an early published report [86] and, consistently, in 19/58
(33%) of a recent case series, [102]. Whilst this level is still
greater than that of a population series, (which ranges from
7% in southern Europeans to 21% in Anglo-Celts [103]),
these observations suggest that the majority of CRCs arising
in serrated polyposis developwithin lesions not known to be
involved in the canonical serrated pathway (see Figure 3).
The balance of CRC (BRAF wild-type) in serrated poly-
posiseitherdemonstratessomaticKRASmutationatarateof
approximately19%which ishalfthatofthepopulation[102]
or is oncogene mutation null. These CRCs may arise, in the
manner of common CRC, from the conventional adenomas
which frequently coexist in patients with serrated polyposis
[17, 23]. Of interest, in reporting the ﬁrst autosomal domi-
nant family with serrated neoplasia, Jeevaratnam et al. made
note of an adenomatous precursor in contiguity with a small
CRC[39] and concludedthat the CRCs in serrated polyposis
arise through both the development of dysplasia in serrated
polyps and through coincident conventional adenomas. In
2010, Pai et al. published a report which examined the
adenomas which coexisted with SSA/P in the general (non-
syndromic) population [105]. They observed that 35% of
the polyps removed from population patients with an index
SSA/P were conventional adenomas. Pai et al. observed 3
morphologicfeatureswhichweremoreprevalentinthestudy
adenomas compared to control adenomas in a population
without SSA/P: eosinophilic cytoplasm, focal (rather than
widespread) serration, and crypt dilatation. These features
were seen in 30% of the study adenomas compared to 2.5%
of controls. In addition, these atypical polyps demonstrated
low levels of methylation, and increased staining for MUC6,
properties more associated with serrated lesions than with
adenomas. Importantly, none of these lesions showed BRAF
mutation. Given previous ﬁndings from the same group of
authors which demonstrated that patients with an index
SSA/P had a signiﬁcantly increased risk of having other
serrated polyps, combined with the presence of atypical con-
ventional adenomas, supports the presence of an epigenetic
ﬁeld defect in serrated polyp patients including those not
meeting the criteria for serrated polyposis [105, 106].
Small numbers of serrated polyps as well as CRCs with
somatic KRAS mutation are also observed in serrated poly-
posispatients.SomaticKRASmutationstraddlesthedivision
between serrated and adenomatous polyps and is mutually
excluded in lesions bearing BRAF mutation [107]. It is
observed in goblet-cell HPs [85] which rarely undergo
malignant transformation; however, its presence, albeit less
frequently, in advanced serrated polyps [84], in rare con-
tiguous serrated polyps attached to population CRC (Young,
unpublished observations) and in the lesions present in
biallelic mutation carriers for MUTYH [90], suggests that
serrated lesions with KRAS mutations are not completely
devoid of malignant potential.
8.TheSmokingParadoxandSerratedPolyposis
Risk factors for the development of serrated polyps in the
population are similar to risk factors for the development
of conventional adenomas, including alcohol consumption,
low folate intake, and high body mass index [72, 108]. High
calcium intake, hormone replacement therapy, and use of
nonsteroidal anti-inﬂammatory drugs are associated with a
reduced risk. Perhaps the most interesting of risk factorasso-
ciationsinvolvescigarettesmoking.Therelationshipbetween
smoking and colorectal neoplasia has become known as
the smoking paradox in that smoking is associated signiﬁ-
cantly with polyps, but its relationship with CRC is much
weaker. A consistent observation has been the relationship
between smoking and serrated polyps, which has been
analyzed in a number of population-based studies [109].
Three independent studies have demonstrated a concordant
pattern of higher risk estimates for serrated (hyperplastic)
polyps than for conventional adenomas [110–112] in long-
term and current smokers. When both serrated polyps and
conventional adenomas were present [110–112], risks were
higher still. The association ofcurrent smoking with serrated
polypsbeginsveryearlyinserratedneoplasia[113]andisthe
greatest in the distal colon [114], where malignant potential
of the serrated polyps is low. The weak association between
smoking and CRC has been explained by the relationship
being dominated by the serrated pathway subset with BRAF
mutation [115], which accounts for only 15% of CRC.8 Pathology Research International
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Originally the canonical serrated pathway was devised to explain CRC with two highly
associated molecular markers, BRAF mutation and CIMP. BRAF mutation is an early
contrast serrated polyps with BRAF mutation in the distal colon rarely progress to
CRC. Increasing CIMP in progression to CRC is shown as a pale blue arrow.
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event in serrated polyps throughout the colon; however, CIMP is more highly
concentrated in the proximal colon, and therefore most CIMP CRCs are found there. In
Figure 3: The canonical serrated pathway showing progression through MVHP (microvessicular hyperplastic polyp) to SSA/P (sessile
serrated adenoma/sessile serrated polyp) and SSA/P-D (SSA/P with dysplasia) to CRC with CIMP and high levels of BRAF mutation
frequently arising in the proximal colon.CRC with CIMP can evolve into MSI-H and non-MSI-H subtypes. Though KRAS mutation can be
observed in CIMP CRC, these are relatively rare [103, 104].
The role of smoking in serrated polyposis has not
been extensively explored. In 2010, several reports added
to the puzzle surrounding the smoking paradox. Initially it
was demonstrated that current smoking is associated with
a signiﬁcantly higher polyp count in patients with serrated
polyposis [11]. Also in 2010, a report suggesting a causative
role for smoking was published on a small series of cases
and showed a higher prevalence of current smokers amongst
serrated polyposis patients than in the population [116].
Given that current smoking is associated with increased
serrated polyps [114] and even serrated aberrant crypt
foci in the general population [113], both the preceding
observations in serrated polyposis patients are reasonable.
Later in 2010, the authors of this current review reported
that, even though current smoking was associated with
increased polyp numbers, there was no signiﬁcant eﬀect on
the risk of CRC in a case series of 151 patients with serrated
polyposis[12],onceagainhighlightingthesmokingparadox.
Given that the major association between smoking and CRC
is largely conﬁned to those CRCs with somatic BRAF muta-
tion, and less than one-third of CRCs in serrated polyposis
harbor a BRAF mutation, this is perhaps not unexpected,
as BRAF-mutated CRCs constitute a minority of serrated
polyposis CRCs. Of interest, however, an unexpected ﬁnding
emerged regarding currently smoking females, who had a
signiﬁcantly decreased risk of CRC, after correcting for age
and adenomas [12] (O.R 0.10, 95% CI 0.02 to 0.47, P =
.004). Further, female patients who had ever smoked had an
average age of onset for CRC of 63 years compared to those
who had never smoked (50 yrs). Though the results did not
reach statistical signiﬁcance due to low numbers, a trend for
delayed onset of CRC in female smokers was evident. In the
population, female smokers with serrated pathway subset
CRC are elderly onset.
The preceding observation is consistent with a biological
mechanism similar to that reported in ulcerative colitis pa-
tients [117] and suggests that perhaps an inﬂammatory pro-
cessmayberesponsibleforneoplastic progressioninserrated
polyposis in a subset of female patients and that, similarly
to ulcerative colitis, smoking may be anti-inﬂammatory. In
the population, a study of risk factors for serrated polyps
demonstrated that aspirin use decreased the risk of advanced
proximal polyps, lending indirect support to this hypothesis
[114]. Alternatively, confounding factors may be responsible
for this ﬁnding, including unspeciﬁed sex-speciﬁc factors
related to body mass index (BMI) or hormonal factors, as
o b s e r v e di nt h ep r o t e c t i v ee ﬀectsof smoking on endometrial
cancer. This ﬁnding whilst perplexing cannot be ignored
because it couldpotentially lead to a CRC-preventivemodal-
ity forfemale patientswith serrated polyposisindependent of
cigarette smoking and its attendant harms.
9.Serrat edP olypos isasaGen etic
PredispositionSyndrome
Serrated polyposis has many hallmarks of a genetic predis-
position. These includean earlierage ofonset ofCRC,polyp,
and cancer multiplicity, increased CRC risk in both patients
and their relatives, and restricted ethnicity. An importantPathology Research International 9
clinical consequence associated with serrated polyposis is
the increased risk of both CRC [26, 39, 43, 44, 54]a n d
possibly extracolonic cancers [27, 118, 119]i nt h ef a m i l y
setting of serrated polyposis patients. The risk to ﬁrst-degree
relatives of CRC has been estimated at ﬁvefold greater than
that of the general population [10]. WHO Criterion 2 (Text
Box 2) addresses the evidence that serrated polyposis may
occur in a familial context [25, 26, 40, 43, 48, 54, 61]a n d
elevates the signiﬁcance of smaller numbers of hyperplastic
polypsin a ﬁrst-degree relative ofan individual with serrated
polyposis. The genetic basis for serrated polyposis is yet to be
determined,though small numbers ofpatientshave reported
mutations in MUTYH [90], PTEN [120], and EPHB2 [121].
Biallelic MUTYH mutation is a phenotypically diverse
disorder which appears to interact with the genetic back-
ground of the individual. In one-third of biallelic mutation
carriers, there are no adenomas present [122]. In approxi-
mately1%ofpatientswith serrated polyposis,biallelicmuta-
tion of MUTYH can be demonstrated [123]. Conversely,
when biallelic MUTYH mutation carriers are assessed, 18%
meet the WHO criteria for serrated polyposis [90]. A recent
report from Buchanan et al. [124] suggests that individuals
withbothMUTYH-associated polyposis(MAP)andserrated
polyposis may be segregating two conditions with diverse
modes of inheritance. The report describes a 56-year-old
Caucasian male with >100 colonic polyps (approximately
50 conventional 10–15mm adenomas predominating in the
proximal colon and approximately 50 < 5mm serrated
polyps in the distal colon and rectum) who also demon-
strated biallelic mutation for the two common European
variants in MUTYH [124]. His mother had CRC of the
sigmoid colon at 70 yrs. His 17-year-old symptomatic son
who was not a biallelic mutation carrier had multiple 4mm
hyperplastic polyps in the rectosigmoid. The implications of
this case report are that the risk to ﬁrst-degree relatives of
biallelicMUTYH mutationcarriers(RR<1.5)[125]isn ota s
s u b s t a n t i a la si ns e r r a t e dp o l y p o s i sw h e r et h er i s ki sﬁ v e f o l d
greater than the population risk [10]. Therefore screening
protocols in the setting described need also to consider the
extra risk to ﬁrst-degree relatives that serrated polyposis can
pose. For this reason, detailed pathological examination of
the polyps in patients with MAP is recommended to exclude
coexisting serrated polyposis. Should serrated polyposis also
be present, screening beyond siblings should be considered.
The evidence that serrated polyposis is a genetic predis-
position is accumulating. Though multiple cases of serrated
polyposis within a single family are rare [39, 54], the phe-
notype of multiple neoplasms, young-onset, and occasional
aﬀected sibships including consanguineous kindreds [26]
suggest apatternof inheritance consistent with an autosomal
recessive or codominant mode [13, 126]. Codominant
modes of inheritance result in an intermediate phenotype
when one variant risk allele is present and a signiﬁcantly
altered phenotype in those where both alleles are variants.
10.Surveillanceand Cancer
PreventionApproaches
Several reports have suggested that malignant transforma-
tion in the serrated pathway may be unusually rapid in some
clinical settings. Despite these observations, the apparent
rapid evolution to cancer of advanced serrated polyps
remains unproven and may be due to the diﬃculty of visual-
izingﬂatserrated lesionsatcolonoscopy.SSA/Pprogress very
slowly to dysplasia in a population cohort [62]; however, in
the syndromic patient this progression may be more rapid
in an epigenetically abnormal environment. Hyman and
colleagues reported 3 cases of serrated polyposis where CRC
developed despite colonoscopy every 2 years [43]. Similarly,
Azimuddin and colleagues reported that colonoscopy every
3 years was inadequate for some families with atypical
serrated polyps [40]. Boparai et al. reported that 5 of 77
serrated polyposis patients developed a CRC whilst under
surveillance for 5 years [9]. In four of ﬁve, the CRC arose
within 12 months of a previous colonoscopy; however, many
polyps had been left in situ. Currently, the issue of rapid
evolution in serrated polyposis remains unresolved.
There are no clear guidelines though recommendations
are evolving [127]. Frequent surveillance colonoscopy in
the initial period after diagnosis both to allow endoscopic
control of the polyps and to determine the nature and
progress of the disease appears justiﬁed. Appropriate sub-
sequent surveillance intervals can then be determined, but
to avoid interval CRC this is unlikely to extend beyond
2-3 year intervals. Referral to a tertiary centre should be
planned particularly ifthepolypburdenisdiﬃculttocontrol
endoscopically and surgery is being considered.
11.Summaryand FutureDirections
Serrated polyposis is a condition with an increased CRC risk
to both individuals and their relatives. An understanding
of the mechanism of malignant transformation in serrated
polyposis is still evolving, along with the risk factors which
inﬂuence it [96]. Without a known germline sequence vari-
ant and estimated genetic penetrance, the identiﬁcation and
management of individuals and their families with a CRC
predispositionsyndrome becomeincreasingly problematical.
The prospect of a syndrome with a codominant mode of
inheritance presents particular diﬃculties in that, although
some individuals will present with a ﬂorid phenotype, such
as that seen in serrated polyposis, ﬁrst-degree relatives
may have only a few polyps or none at all. The role
of genetics departments, pathologists, and endoscopists in
understanding the clinical picture for such families is likely
to become increasingly important and interdependent. The
challenge will be to determine if we can conﬁdently identify
and assign CRC risks to the diﬀerent phenotypes of serrated
polyposis, thereby allowing tailored clinical management
with regard to the frequency of colonoscopic surveillance,
the aggressiveness of polyp removal, and consideration of
colonic resection.10 Pathology Research International
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